Navigation Links
Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
Date:12/28/2007

iance may receive milestone payments on future sales.

Zensana(TM) (ondansetron HCI) Oral Spray:

In August 2007, Par Pharmaceutical, Inc. acquired the North American commercial rights to Zensana(TM) from Hana Biosciences, Inc. Ondansetron is used to prevent nausea and vomiting after chemotherapy, radiation and surgery. Following successful development and approval, Zensana(TM) could be among the first in its class of 5-HT3 antagonist anti-emetic therapies to be available in an oral spray form.

Under a development agreement with Novadel Pharma, Inc., Par has completed its reformulation of Zensana(TM) and is preparing for the requisite studies to reconfirm the product's pharmacokinetic profile and confirm stability acceptability. These studies are expected to be completed by the end of 2008 with an NDA to be filed shortly thereafter.

In return for the North American commercial rights to Zensana(TM), Par made a $5 million equity investment in Hana. In addition, Hana may receive future milestone payments and royalties on future sales of the product.

John MacPhee, president of Strativa Pharmaceuticals, said, "We are excited about our current pipeline and look forward to bringing these innovative treatment options to patients and their healthcare providers. In addition, we will continue to pursue products that leverage our commercial presence and expertise in supportive care in oncology and AIDS."

About Strativa

Strativa Pharmaceuticals is the proprietary products division of Par Pharmaceutical, Inc. Supported by Par's financial and organizational capabilities including substantial cash resources, Strativa Pharmaceuticals is committed to developing and marketing novel prescription drugs. Its initial focus is on supportive care therapeutics in HIV and oncology. Drawing on the specialty products expertise of its staff, Strativa possesses the resources to prepare products for introduction and to help ensure their success after
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Introducing Strativa Pharmaceuticals
2. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
3. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
4. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
5. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
6. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
7. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
8. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
9. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
10. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Proove Biosciences ... will be exhibiting data and research conducted through their ... Spine Intervention Society’s (ISIS) 22nd Annual Scientific Meeting. ... the Hyatt Regency, in Orlando, Florida. , ... clinical competence of physicians who care for patients suffering ...
(Date:7/28/2014)... July 28, 2014 Immunomic Therapeutics, Inc. ... to further develop potential treatments for glioblastoma multiforme (GBM), ... combination with their patented vaccine platform, LAMP-vax. , ... are based on the work of John H. Sampson, ... The Preston Robert Tisch Brain Tumor Center at Duke ...
(Date:7/28/2014)...  InterMune, Inc. (NASDAQ: ITMN ) today ... financial results at the close of the U.S. markets ... webcast will be hosted by InterMune at 4:30 p.m. ... and others may participate in the conference call by ... replay of the webcast and teleconference will be available ...
(Date:7/25/2014)... "Ischemic Stroke and Cerebral Stroke ... on the Ischemic Stroke and Cerebral Stroke clinical ... data relating to the clinical trials on Ischemic ... Ischemic Stroke Research Report 2014 at: http://www.marketresearchreports.biz/analysis/213207 ... trial numbers and their recruitment status as per ...
Breaking Biology Technology:Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4InterMune to Release Second Quarter Financial Results on August 6 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3
... Jan. 11, 2011 SeqWright Inc., a world-wide ... continues to make significant strides to position itself ... 2011. SeqWright,s ongoing success can be attributed to ... demands and by investing in key genomics technologies. ...
... and NASHVILLE, Tenn., Jan. 11, 2011 AstraZeneca (NYSE: ... (SCRI), an international leader in advancing therapies for cancer ... lead the clinical development of a novel targeted oncology ... major cause of mortality globally; accounting for 7.4 million ...
... York, NY, 10 January 2011 Elsevier ... Diamond, Diamond-Like Materials, Carbon Nanotubes and Nitrides, will occur ... Elsevier organized conference discusses the significant improvements in material ... over the past few years. The improvements have lead ...
Cached Biology Technology:SeqWright Continues Expansion of Next-Generation Sequencing Capabilities 2AstraZeneca and Sarah Cannon Research Institute Join Efforts to Fight Cancer 2AstraZeneca and Sarah Cannon Research Institute Join Efforts to Fight Cancer 3
(Date:7/28/2014)... prevent and treat HIV infection has been problematic until ... can arouse as they get rid of the invaders. ... Institute and the National Institutes of Health (NIH) have ... interferons around the time of infection could have ... research appeared in Nature . , Interferons, ...
(Date:7/27/2014)... revealed that nicotine and cotinine, a metabolite of nicotine, ... carcinogen in smoke. , The carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone or NNK ... ultimately ends up in the tobacco smoke. Once inhaled, ... it is activated by a variety of enzymes called ... that nicotine can partially interfere with the activation of ...
(Date:7/27/2014)... global climate change to cut food supplies. But these ... between increasing temperature and air pollution specifically ozone ... new study involving researchers at MIT shows that these ... to take both warming and air pollution into account ... detail at global production of four leading food crops ...
Breaking Biology News(10 mins):Interfering with interferon 2Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Study: Climate change and air pollution will combine to curb food supplies 2Study: Climate change and air pollution will combine to curb food supplies 3
... BOSTON--Scientists at Dana-Farber Cancer Institute have uncovered the mechanism ... cancer cells, DNA with potent drugs while simultaneously preventing ... reported in the Aug. 14 issue of Molecular ... in clinical trials of compounds that force cancer cells ...
... toxin in an amphibian a 60 amino acid neurotoxin found ... may help shed more light into both the evolution of ... protein toxins have been identified in many vertebrate animals, including ... amphibians or birds. In the case of poisonous amphibians, like ...
... San Antonio Tao Weitao, a researcher in the College ... at San Antonio is making great strides in a project ... Area Foundation. The professor in the South Texas Center ... a soil-dwelling bacterium that threatens the health of military personnel ...
Cached Biology News:Study supports DNA repair-blocker research in cancer therapy 2Study supports DNA repair-blocker research in cancer therapy 3UTSA biology researchers demystify elusive war zone bacterium 2
... operate as a Voltage Clamp, as a Current ... electrophysiology research applications. Performance in any one mode ... • This amazing instrument is ... capabilities of Digital Signal Processing (DSP) integrated circuit ...
... Identical to the DH-2000, but comes with ... switch up to 5 Hz) The ... the continuous spectrum of deuterium and tungsten halogen ... combined-spectrum light source produces a powerful, stable output ...
... in g per ml and is determined from ... of a 1 mg per ml solution. ... agglutinate a 2% suspension of human blood group ... C. Preparation Note: Affinity purified by ...
... The MSD Security ChemStation ... GC/MS software application for ... quantification, library searching and ... aspects of data security, ...
Biology Products: